Getinge’s organic sales growth slowed to 2.1% in the third quarter from 4.6% in the previous quarter. The slowdown was driven by persistent weakness in life science capital goods and lumpy ventilator procurement. Shares increased by 2% at the market open on Oct. 21.
Getinge benefits from stable long-term growth trends such as an aging population and increased healthcare spending, which are generally not affected by macroeconomic circumstances.
Getinge’s China business, which we estimate to be roughly 10% of total sales, is facing a slowdown, similar to that of its life science peers.
Metric | GETI B | MDT | SYK |
|---|---|---|---|
Price/Earnings (Normalized) | 22.87 | 17.95 | 22.71 |
Price/Book Value | 2.26 | 2.59 | 5.26 |
Price/Sales | 2.14 | 3.48 | 4.76 |
Price/Cash Flow | 13.93 | 14.58 | 23.30 |
Metric | GETI B | MDT | SYK |
|---|---|---|---|
Quick Ratio | 0.72 | 1.29 | 1.07 |
Current Ratio | 1.25 | 2.07 | 2.18 |
Interest Coverage | 7.91 | 10.12 | 9.73 |
Metric | GETI B | MDT | SYK |
|---|---|---|---|
Return on Assets (Normalized) | 6.11% | 8.31% | 11.66% |
Return on Equity (Normalized) | 11.50% | 15.59% | 24.04% |
Return on Invested Capital (Normalized) | 9.40% | 10.57% | 15.46% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|q%Z>&?R | LOCK|H>$^m | $191B | |||
| Medtronic PLC MDT | LOCK|&K@?v^t | LOCK|j@STX | $130B | |||
| Stryker Corp SYK | LOCK|VwCD?Yw | LOCK|g& | $123B | |||
| Boston Scientific Corp BSX | LOCK|%%#F!w^ | LOCK|$#G!^ | $65B | |||
| Edwards Lifesciences Corp EW | LOCK|qhM!<Rr | LOCK|?Lfg | $60B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|%p>MB& | LOCK|?$ | $38B | |||
| DexCom Inc DXCM | LOCK|mb&z^%>F | LOCK|BB$lP | $30B | |||
| Koninklijke Philips NV ADR PHG | LOCK|!B | LOCK|^?< | $30B | |||
| Steris PLC STE | LOCK|Y?$$x! | LOCK|$pxL | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|ZSQV<wG! | LOCK|Gx | $20B |
United States